Apreszine 25

Apreszine 25

hydralazine

Manufacturer:

Community Pharm PCL

Distributor:

Community Pharm PCL

Marketer:

Community Pharm PCL
Concise Prescribing Info
Contents
Hydralazine HCl
Indications/Uses
Adjunct to other antihypertensive in the management of moderate to severe HTN.
Dosage/Direction for Use
Initially 25 mg bid for the first 2-4 days. Increase to 25 mg qid for balance of the 1st wk. Dosage titration: 50 mg qid from the 2nd wk. Maintenance dose: Up to 300 mg/day in resistant patients.
Administration
May be taken with or without food.
Contraindications
Hypersensitivity. CAD; mitral valvular rheumatic heart disease. Patients w/ severe tachycardia, dissecting aortic aneurysm, heart failure w/ high cardiac output, cor pulmonale, or myocardial insufficiency due to mechanical obstruction eg, aortic or mitral stenosis or constrictive. Idiopathic SLE & related disorders.
Special Precautions
Discontinue therapy if blood dyscrasias (eg, Hb & RBC count reduction, leucopenia, agranulocytosis, purpura) occur. May cause a drug-induced lupus-like syndrome including glomerulonephritis in patients receiving higher doses. Postural hypotension. Patients w/ CVA & suspected CAD; advanced renal impairment. May produce myocardial stimulation causing angina attacks & ECG changes of myocardial ischemia; MI. May increase pulmonary artery pressure in patients w/ mitral valvular disease. Initiate pyridoxine therapy w/ peripheral neuritis. Advanced renal impairment.
Adverse Reactions
Headache, anorexia, nausea, vomiting, diarrhea, palpitations, tachycardia, angina pectoris.
Drug Interactions
May increase the levels/effects of amifostine, antipsychotics (2nd generation), bromperidol, duloxetine, hypotension associated agents, levodopa, nitroprusside, pholcodine. Levels/effects may be increased by alfuzosin, barbiturates, benperidol, brigatinib, topical brimonidine, dapoxetine, diazoxide, herbs (hypotensive properties), lormetazepam, molsidomine, naftofpidil, nicergoline, nicorandil, obinutuzumab, pentoxifylline, phosphodiesterase 5 inhibitors, prostacyclin analogues, quinegolide. Levels/effects may be decreased by amphetamines, brigatinib, bromperidol, herbs (hypertensive properties), methylphenidate, NSAIDs, yohimbine.
ATC Classification
C02DB02 - hydralazine ; Belongs to the class of hydrazinophthalazine derivatives. Used in the treatment of hypertension.
Presentation/Packing
Form
Apreszine 25 FC tab 25 mg
Packing/Price
50 × 10's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in